Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond

Roche continues to expand the Integrated Core Lab by consolidating and integrating a wider range of platforms across other disciplines that include molecular diagnostics and testing in coagulation, hematology and urinalysis. Roche solutions are also designed to address the lab's future needs, with pre-analytics and the next generation of automation that provides the ability to expand into liquid-based cytology and compatible analytics, all potentially connectable. The automation area included a fully automated configuration of an integrated core lab that consolidates routine chemistry and molecular testing.

Among the products highlighted by Roche at AACC 2019 was its cobas pro integrated solutions — an integrated mid-to-high volume solution for clinical chemistry and immunochemistry testing needs that is designed to achieve reduced maintenance and increased throughput through a scalable and modular system. The company showcased cobas prime — a pre-analytical system designed for standard processing and cross-contamination control of molecular samples — and cobas e 801 module — a high-volume immunoassay platform that provides nearly twice the throughput on the same footprint as its predecessor.

Roche also showcased cobas c 513 — a fully automated chemistry analyzer that raises the standard in HbA1c testing throughput — and the cobas 6800 system — a fully-automated, moderate-complexity platform that brings transformational efficiency gains to molecular diagnostics. The company also highlighted the cobas Connection Module (CCM) — a high-volume automation solution that provides connectivity across disciplines and third-party platforms — and the cobas Liat PCR system — a point-of-care analyzer with CLIA-waived, real-time PCR tests for flu A/B, flu A/B + RSV and strep A that provide lab-quality results in 20 minutes or less.